Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 7/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.59 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30186436 | 0.88 | CXCR4 (0.58) | — | |
| SCHEMBL30607473 | 0.88 | NPY2R (0.63) | — | |
| SCHEMBL30802597 | 0.87 | NTSR1 (0.60) | OPRM1NTSR1NTSR2 | |
| SCHEMBL30495628 | 0.87 | OPRD1 (0.61) | OPRD1OPRM1 | |
| SCHEMBL30512571 | 0.87 | OPRD1 (0.61) | OPRD1OPRM1NTSR1F2NTSR2 | |
| SCHEMBL30512664 | 0.86 | OPRD1 (0.62) | OPRD1OPRM1NTSR1 | |
| SCHEMBL29596671 | 0.86 | GRB2 (0.48) | OPRD1OPRM1NTSR1F2NTSR2 | |
| SCHEMBL30932399 | 0.86 | CALCRL (0.55) | OPRD1OPRM1F2 | |
| SCHEMBL29714014 | 0.85 | NTSR1 (0.64) | OPRM1NTSR1NTSR2 | |
| SCHEMBL30444236 | 0.85 | SLC6A2 (0.62) | OPRD1OPRM1NTSR1F2NTSR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024211447-A1 | TP508 MRNAS | CHRYSALIS BIOTHERAPEUTICS (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20230165943-A1 | TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION | CHRYSALIS BIOTHERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| EP-4132948-A1 | TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION | Chrysalis Biotherapeutics (US) | 2023-02-15 | — | — | EP | disclosed |